A Retrospective Study of Drug Used and Potential Drug Interactions in Patients with Systemic Lupus Erythematosus
Keywords:penggunaan obat, potensi interaksi obat, SLE
Systemic Lupus Erythematosus is a complex autoimmune disease involving multiple organs with various clinical manifestations and prognoses. The complexity of treatment and the emergence of drug-related problems demands a greater role of pharmacy in conducting pharmaceutical care. The aim of this study was to explore drug use and to identify potential drug interactions in SLE outpatients at one hospital in Denpasar. This study was a retrospective and observational study collection. The study used secondary data in medical records during January-December 2019. There were 210 SLE people consisting of 12.86% males and 87.14% women. 29.05% of the patients were aged 17-25 years. The most immunosuppressants used were methylprednisolone (48.93%), the most analgetic used was acetaminophen (88.46%). 12.10% of patients had a potentially serious drug interaction, 80.40% had a moderate and 7.5% had minor drug interaction.
American Pharmacist Ascotiation. (2017). Drug Information Handbook: A Clinically Relevant Resource for All Healthcare Professionals. United State: Wolters Kluwer.
Barber, M. R. W., & Clarke, A. E. (2020). Systemic lupus erythematosus and risk of infection. Expert Review of Clinical Immunology, 16(5), 527–538.
Brinks, R., Hoyer, A., Weber, S., Fischer-Betz, R., Sander, O., Richter, J. G., … Schneider, M. (2016). Age-specific and sex-specific incidence of systemic lupus erythematosus: an estimate from cross-sectional claims data of 2.3 million people in the German statutory health insurance 2002. Lupus Science & Medicine, 3(1), e000181.
Choi, M. Y., Barber, M. R. W., Barber, C. E. H., Clarke, A. E., & Fritzler, M. J. (2016). Preventing the development of SLE: identifying risk factors and proposing pathways for clinical care. Lupus, 25(8), 838–849.
Cunha, J. S., & Gilek-Seibert, K. (2016). Systemic lupus erythematosus: A review of the clinical approach to diagnosis and update on current targeted therapies. Rhode Island Medical Journal, 99(12), 23.
Kamal, M. A., & Jusko, W. J. (2014). Interactions of Prednisolone and Other Immunosuppressants Used in Dual Treatment of Systemic Lupus Erythematosus in Lymphocyte Proliferation Assays. Journal of Clinical Pharmacology, 44(9), 1034–1045. https://doi.org/10.1177/0091270004267808.Interactions
Kanukula, R., Esam, H., Sundström, J., Rodgers, A., & Salam, A. (2019). Does Co-administration of Antihypertensive Drugs and Statins Alter Their Efficacy and Safety? A Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal of Cardiovascular Pharmacology, 73(6), 352–358.
Kementerian Kesehatan Republik Indonesia. (2017). Situasi Lupus di Indonesia. Pusat Data dan Informasi Kementerian Kesehatan Republik Indonesia.
Kuhn, A., Bonsmann, G., Anders, H.-J., Herzer, P., Tenbrock, K., & Schneider, M. (2015). The diagnosis and treatment of systemic lupus erythematosus. Deutsches Ärzteblatt International, 112(25), 423.
Perhimpunan Reumatologi Indonesia. (2019). Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik. Jakarta: Perhimpunan Reumatologi Indonesia.
Sciascia, S., Cuadrado, M. J., & Karim, M. Y. (2013). Management of infection in systemic lupus erythematosus. Best Practice & Research Clinical Rheumatology, 27(3), 377–389.
Tian, J., Luo, Y., Wu, H., Long, H., Zhao, M., & Lu, Q. (2018). Risk of adverse events from different drugs for SLE : a systematic review and network meta-analysis. 1–9. https://doi.org/10.1136/lupus-2017-000253
Touma, Z., & Gladman, D. D. (2017). Current and future therapies for SLE : obstacles and recommendations for the development of novel treatments. Lupus Science and Medicine, 4, 1–11. https://doi.org/10.1136/lupus-2017-000239.
How to Cite
Copyright (c) 2021 Jurnal Ilmiah Medicamento
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The copyright holder for the work is the Jurnal Ilmiah Medicamento.
Jurnal Ilmiah Medicamento is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- The licensor cannot revoke these freedoms if you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so reasonably but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.